公司资料
Larimar Therapeutics 股价、新闻与催化剂
- 股票代码:
- LRMR
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
4.18 USD (+0.48%)
收盘价
最后更新: 2026年8月21日
343M USD
市值
股价为何变动
As of Aug 21, 2026, LRMR closed up 0.48% at $4.18. No new same-company headline was identified in the current news window.
公司概览
Intracellular Protein Delivery
Larimar Therapeutics develops fusion proteins that deliver functional biological material into cells. Its lead program addresses a rare disease caused by deficiency of the intracellular protein frataxin.
Nomlabofusp
Nomlabofusp is a recombinant fusion protein designed to deliver human frataxin into the mitochondria of patients with Friedreich’s ataxia. The therapy is intended to address the underlying protein deficiency rather than only manage disease symptoms.
Accelerated-Approval Strategy
Larimar is working with the FDA on a BLA using skin frataxin as a biomarker and matched natural-history comparisons for clinical outcomes. A global confirmatory Phase 3 trial is planned to be underway at submission and uses change in the Upright Stability Score as its primary endpoint.
Platform Expansion
Beyond Friedreich’s ataxia, Larimar intends to use its intracellular delivery technology to create fusion proteins for other rare diseases caused by deficiencies in intracellular bioactive compounds.
未来催化剂
- Topline open-label nomlabofusp data expected in the second quarter of 2026.
- Start of screening for the confirmatory Phase 3 study expected in the second quarter of 2026, with first dosing around mid-2026.
- Nomlabofusp BLA submission seeking accelerated approval planned for June 2026.
- Potential U.S. launch targeted for the first half of 2027, subject to approval.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。